SCIENCE WITHOUT BORDERS. MADE FOR THE MIDDLE EAST.FOR LABORATORY RESEARCH ONLYA CONSIDERED APPROACH TO RESEARCH
SILSILA / SCIENCE & JOURNAL

Peptide science. The evidence.

Small molecules, a growing scientific story — from cellular signals to approved medicines and ongoing studies.

Explore the journal
100+years of peptide medicine since 1922
2–50amino acids in a typical chain
17,600+participants in the heart trial
8source-linked journal topics
THE FOUNDATIONS

Small chains, diverse roles

Peptides are amino-acid chains joined by peptide bonds. Some act as biological signals; their effects depend on structure, targets and how they are studied. Laboratory findings, clinical trials and approval of a specific medicine are different kinds of evidence.

PubMed · Biochemistry, Peptide
Researcher in a laboratory
SCIENTIFIC MILESTONES

Documented progress

1922

Insulin

Successful clinical treatment of diabetes with insulin was reported in 1922.

PMC · Historical review
2019

Oral semaglutide

The FDA approved Rybelsus tablets for adults with type 2 diabetes, alongside diet and exercise.

US FDA · Approval letter
2024

Cardiovascular progress

The FDA added a Wegovy indication to reduce major cardiovascular risks in adults with cardiovascular disease and overweight or obesity.

US FDA · Approval announcement
FROM THE FDA REPORT

A clinical finding, in context

MAJOR CARDIOVASCULAR EVENTS · WEGOVY6.5%

Versus 8% with placebo in the trial supporting approval.

MULTINATIONAL STUDY17,600+

Participants with cardiovascular disease and overweight or obesity; both groups received standard care and lifestyle counseling.

SPECIFIC INDICATION APPROVAL2024

FDA approval applies to Wegovy and its indication, not to Silsila products.

Read the original FDA report

For education, not medical advice. Silsila products are for laboratory research; results for an approved medicine do not establish their safety or effectiveness.

SILSILA / OUR STORY

Our story

Silsila — a Gulf-born science team building the region's peptide brand.

How it began

Silsila is a small, focused company from the Gulf region, built around a team with a genuine passion for science — and above all, peptides. What began as curiosity grew into years of reading, discussing and studying peptide science, from how these molecules work to how the world's finest laboratories produce them, and on into deep research of the companies manufacturing them across continents — building real international relationships that led, step by step, to the best factories and the most trusted suppliers in the field. With those partnerships in place, Silsila created Silsila: its own peptide brand, made with the partners it came to know best and backed by years of research and substantial investment to guarantee the highest scientific and quality standards in everything from sourcing to storage to support. The ambition is clear — to become the first and the finest peptide brand in the Gulf region and the wider Middle East, and one day to carry it to the world.

A word from the CEO & Founder

When we started Silsila, we were simply a team that loved science and believed in the promise of peptides. Years of research, partnerships and careful investment later, Silsila exists to bring that same standard of quality and clarity to the Gulf and the wider Middle East. We built this brand the long way — on relationships, evidence and patience — and we intend to keep it that way. Our promise is simple: the best quality and the best service possible, at every step.

— CEO & Founder
THE SCIENCE JOURNAL

Explore the evidence

From the foundations to published studies and regulatory sources.